The first patent application describes an anti-HIV utility. The second application describes a new utility of the deoxyribo derivatives of the first application, namely as anti-Herpes Virus agents. The thymidine analog, in particular, showed good activity against Herpes Simplex Type 1 and Herpes Simplex Type 2 viruses, and Epstein-Barr virus as shown in an in vitro assay. It showed better antiherpes activity than acyclovir in a plaque reduction assay. T cells play both regulatory and effector functions in human immune responses that are often mediated by interleukins.
Interleukins are highly redundant and pleitrophic, controlling a wide range of functions.